IL319922A - Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer - Google Patents

Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Info

Publication number
IL319922A
IL319922A IL319922A IL31992225A IL319922A IL 319922 A IL319922 A IL 319922A IL 319922 A IL319922 A IL 319922A IL 31992225 A IL31992225 A IL 31992225A IL 319922 A IL319922 A IL 319922A
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
acceptable salt
enzalutamide
talazoparib
subject
Prior art date
Application number
IL319922A
Other languages
Hebrew (he)
Inventor
Akos Gabor Czibere
Dana Ann Kennedy
Maria Teresa Koehler
Sandra Jean Meech
Fong Wang
Original Assignee
Pfizer
Astellas Pharma Inc
Akos Gabor Czibere
Dana Ann Kennedy
Maria Teresa Koehler
Sandra Jean Meech
Fong Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Astellas Pharma Inc, Akos Gabor Czibere, Dana Ann Kennedy, Maria Teresa Koehler, Sandra Jean Meech, Fong Wang filed Critical Pfizer
Publication of IL319922A publication Critical patent/IL319922A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (23)

What is claimed is:
1. Talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use in a method of treating metastatic castration-resistant prostate cancer in a subject in need thereof, for once daily orally administeration to a subject, wherein the administration of the talazoparib, or a pharmaceutically acceptable salt thereof, and the administration of the enzalutamide, or a pharmaceutically acceptable salt thereof, increases survival in the subject.
2. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 1, wherein the metastatic castration-resistant prostate cancer is metastatic castration-resistant prostate cancer with or without homologous recombination repair (HRR) gene mutations.
3. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 1 or claim 2, wherein the subject has not received: 1) systemic cancer treatment for non-metastatic castration-resistant prostate cancer or metastatic castration-resistant prostate cancer; 2) treatment with an androgen receptor signaling inhibitor, a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer; or 3) treatment with platinum-based chemotherapy within 6 months or any history of disease progression on platinum-based therapy within 6 months.
4. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 3, wherein the subject is additionally receiving a gonadotropin releasing hormone analog or has had a bilateral orchiectomy.
5. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 4, wherein the gonadotropin releasing hormone analog is a gonadotropin releasing hormone agonist or a gonadotropin releasing hormone antagonist.
6. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 5, wherein the subject is unselected for DNA damage response (DDR) mutation status.
7. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 6, wherein survival is radiographic progression free survival.
8. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 7, wherein radiographic progression free survival is increased as compared to a subject who has received enzalutamide, or a pharmaceutically acceptable salt thereof, and placebo.
9. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 6, wherein survival is overall survival.
10. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 9, wherein overall survival is increased as compared to a subject who has received enzalutamide, or a pharmaceutically acceptable salt thereof, and placebo.
11. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 6, wherein survival is a significantly reduced risk of disease progression or death, as compared to a subject who has received enzalutamide, or a pharmaceutically acceptable salt thereof, and placebo.
12. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 11, wherein the significantly reduced risk of disease progression or death is at least a 37% reduction, as compared to a subject who has received enzalutamide, or a pharmaceutically acceptable salt thereof, and placebo.
13. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 12, wherein the talazoparib, or pharmaceutically acceptable salt thereof, is administered at a dosage equivalent to about 0.1 mg, about 0.25 mg, about 0.mg or about 0.5 mg once daily of talazoparib free base.
14. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 13, wherein the talazoparib, or pharmaceutically acceptable salt thereof, is administered at a dosage equivalent to about 0.35 mg once daily of talazoparib free base and further wherein the subject has moderate renal impairment.
15. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 14, wherein the talazoparib, or pharmaceutically acceptable salt thereof, is talazoparib tosylate.
16. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 15, wherein the enzalutamide, or pharmaceutically acceptable salt thereof, is administered at a dosage equivalent to about 160 mg once daily of enzalutamide free base.
17. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 16, wherein the dosage of enzalutamide, or a pharmaceutically acceptable salt thereof, is reduced, if enzalutamide, or a pharmaceutically acceptable salt thereof, is dosed concomitantly with a strong CYP2C8 inhibitor.
18. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 17, wherein the dose of enzalutamide, or a pharmaceutically acceptable salt thereof, is reduced to 80 mg once daily.
19. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 16, wherein the dose of enzalutamide, or a pharmaceutically acceptable salt thereof, is increased if the enzalutamide is dosed concomitantly with a CYP3A4 inducer.
20. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 19, wherein the dose of enzalutamide, or a pharmaceutically acceptable salt thereof, is increased to 240 mg daily.
21. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any one of claims 1 to 20, wherein the enzalutamide, or a pharmaceutically acceptable salt thereof, is a free base.
22. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of any of the preceeding claims, wherein the subject is a human.
23. The talazoparib, or a pharmaceutically acceptable salt thereof and enzalutamide, or a pharmaceutically acceptable salt thereof for use of claim 22, wherein the human is an adult.
IL319922A 2022-10-02 2023-09-29 Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer IL319922A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263412520P 2022-10-02 2022-10-02
US202263434465P 2022-12-21 2022-12-21
US202363445886P 2023-02-15 2023-02-15
US202363470761P 2023-06-02 2023-06-02
PCT/IB2023/059790 WO2024074959A1 (en) 2022-10-02 2023-09-29 Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Publications (1)

Publication Number Publication Date
IL319922A true IL319922A (en) 2025-05-01

Family

ID=90607623

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319922A IL319922A (en) 2022-10-02 2023-09-29 Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Country Status (10)

Country Link
US (1) US20260108513A1 (en)
EP (1) EP4593828A1 (en)
JP (1) JP2025533012A (en)
KR (1) KR20250070114A (en)
CN (1) CN120302972A (en)
AU (1) AU2023357890A1 (en)
IL (1) IL319922A (en)
MX (1) MX2025003936A (en)
TW (1) TWI883565B (en)
WO (1) WO2024074959A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600137A (en) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor and methods of treatment thereof
WO2026078615A1 (en) * 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) * 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
BRPI0709771B1 (en) 2006-03-27 2022-01-25 The Regents Of The University Of California Compound and pharmaceutical composition
HUE035295T2 (en) 2008-08-06 2018-05-02 Medivation Technologies Inc Poly (ADP-Ribose) Polymerase (PARP) Dihydropyridophthalazinone Inhibitors
AR078793A1 (en) 2009-10-27 2011-12-07 Orion Corp DERIVATIVES OF NON-STEROID CARBOXAMIDS AND ACIL HYDRAZONE MODULATORS OF ANDROGENIC RECEPTORS OF SELECTIVE FABRIC (SARM), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME IN THE TREATMENT OF PROSTATE CANCER BETWEEN OTHERS
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
MX340319B (en) 2010-02-08 2016-07-06 Medivation Technologies Inc Processes of synthesizing dihydropyridophthalazinone derivatives.
CN103282365B (en) 2010-10-21 2017-12-29 麦迪韦逊科技有限公司 (8S, 9R) 5 fluorine 8 (4 fluorophenyl) 9 (base of 1 methyl 1H, 1,2,4 triazoles 5) 8,9 dihydro 2H pyridos [4,3,2 de] phthalazines 3 (7H) ketone toluene fulfonate of crystallization
EP3066084A1 (en) 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
EA201790290A1 (en) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. FORMER SALTS (2S, 3S) -METHyl 7-Fluoro-2- (4-Fluoro-phenyl) -3- (1-Methyl-1H-1,2,4-TRIAZOL-5-IL) -4-Oxo-1,2 , 3,4-TETRAHYDROHINOLIN-5-CARBOXYLATE AND METHODS FOR PRODUCING THEM
CN108883115A (en) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 With PARP inhibitor for treating Small Cell Lung Cancer
AU2018347331A1 (en) 2017-10-13 2020-04-09 Merck Patent Gmbh Combination of a PARP inhibitor and a PD-1 axis binding antagonist
EP4313034A1 (en) 2021-03-24 2024-02-07 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer

Also Published As

Publication number Publication date
JP2025533012A (en) 2025-10-03
AU2023357890A1 (en) 2025-04-17
TWI883565B (en) 2025-05-11
MX2025003936A (en) 2025-05-02
EP4593828A1 (en) 2025-08-06
KR20250070114A (en) 2025-05-20
TW202425975A (en) 2024-07-01
CN120302972A (en) 2025-07-11
WO2024074959A1 (en) 2024-04-11
US20260108513A1 (en) 2026-04-23

Similar Documents

Publication Publication Date Title
Cruz-Burgos et al. New approaches in oncology for repositioning drugs: the case of PDE5 inhibitor sildenafil
USRE49353E1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2024200203B2 (en) Methods for the treatment of recurrent glioblastoma (RGBM)
Jhaveri et al. Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC)
Haus et al. Spectrum of use and tolerability of 5‐HT3 receptor antagonists
JP2015536964A (en) Pharmaceutical combinations comprising B-RAF inhibitors and histone deacetylase inhibitors and their use in the treatment of proliferative diseases
JP2016520622A5 (en)
JP2024510666A5 (en)
KR101628448B1 (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
EP1201247B1 (en) Treatment of metastatic renal cell carcinoma
Sharma et al. New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS)
JP2015514796A (en) Dexanabinol or a derivative thereof for use in treating cancer at doses ranging from 2 to 30 mg / kg
CN120302972A (en) Combination of talazoparib and enzalutamide for the treatment of metastatic castration-resistant prostate cancer
EP4087572A1 (en) Combination therapy for treating cancer
CN116322690A (en) Combination Drug Anticancer Therapy
RU2025107889A (en) COMBINATION OF TALAZOPARIB AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Silvestris et al. Update on capecitabine alone and in combination regimens in colorectal cancer patients
EP4178566B1 (en) Satraplatin for use in the treatment of primary central nervous system lymphoma (pcnsl)
US20120283278A1 (en) Combination
Grothey et al. 295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial
Nalawade et al. Olaparib an anticancer drug: A review
Petrylak et al. EV-301: an open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)
CN106421796B (en) Sorafenib combines CCR4 antagonist and is inhibiting the application in cancer growth and transfer
US20190000779A1 (en) Pharmaceutical formulation
WO2022212631A1 (en) Treatment of patients metastatic castration-resistant prostate cancer with an androgen receptor antagonist